The latest price target for Oncolytics Biotech (NASDAQ:ONCY) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $5.00 expecting ONCY to rise to within 12 months (a possible 367.29% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Oncolytics Biotech (NASDAQ:ONCY) was provided by HC Wainwright & Co., and Oncolytics Biotech reiterated their buy rating.

There is no last upgrade for Oncolytics Biotech

There is no last downgrade for Oncolytics Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncolytics Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncolytics Biotech was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Oncolytics Biotech (ONCY) rating was a reiterated with a price target of $5.00 to $5.00. The current price Oncolytics Biotech (ONCY) is trading at is $1.07, which is out of the analyst’s predicted range.